Major NMSG multicenter studies - ongoing: active including or follow-up

·         MP-T + Thal maintenance vs. MP-R + Rev maintenance as first line treatment in elderly newly diagnosed (phase III, NMSG-HOVON-study; interim at ASH 2014)

·         Cy-Bor-Dex induction followed by MEL200 vs. V-MP x 4, and randomised VRD consolidation vs. no consolidation (phase III, collaboratory EMN-02 Study)

·         Carfilzomib-Cy-Dex re-induction followed by Carfil-Mel200 conditioning/ASCT followed by Carfil vs. no maintenance in  first relapse after prior HDT (phase III)

·         Extended bone protection with zoledronic acid  - 2 vs. 4 years treatment  (phase III)

·         Ixazomib-Thal-Dex induction followed by Ixazomib vs. Placebo maintenance in newly diagnosed, non-transplant eligible MM patients (randomised phase II, NMSG-HOVON)

·         Carfilzomib-Len-Dex induction and auto/allo transplantation in primary plasma cell leukemia (EMN)

Nordic MRD substudy in EMN-02; about 40 patients in CR with sequential BMF



Major NMSG multicenter studies - former and finalized studies

·         NOP in refractory myeloma (phase II) and newly diagnosed myeloma (phase III)

·         MP vs. MP+IFNa (phase III)

·         High-dose chemotherapy + stem cell support in patients < 60 years (vs. historical control)

·         High-dose chemotherapy + stem cell support in patients < 65 years (vs. historical control)

·         Induction chemotherapy VAD vs. Cy-Dex (phase III)

·         Induction chemotherapy Cy-Fludarabin-Dex vs. Cy-Dex (phase II)

·         MP vs. MP-T in elderly newly diagnosed (phase III)

·         Pamidronate 90 mg vs. 30 mg in bone protection (phase III)

·         Bortezomib-Dex vs. Thalidomide-Dex in first relapse (phase III)

·         Bortezomib consolidation vs. no consolidation post-ASCT (phase III)

·         Bortezomib-Dex re-induction  followed by Bortezomib+Melfalan conditioning and ASCT in first relaps after prior ASCT (phase II)